Are you a medical professional seeking the latest information on treating Irritable Bowel Syndrome (IBS)? Look no further than plecanatide, also known as Trulance - a promising new medication that has been shown to effectively relieve IBS symptoms. In this review of recent studies, we'll take a closer look at plecanatide and how it works, as well as any potential side effects you should be aware of. Keep reading to learn more about this exciting treatment option for your patients with IBS.
Plecanatide is a medication used to treat chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C). It belongs to a class of drugs called guanylate cyclase-C agonists, which stimulate the secretion of fluid in the intestines.
Unlike other medications that treat these conditions, plecanatide specifically targets the GC-C receptors found on intestinal cells. This selective targeting allows for more effective treatment with fewer side effects.
Plecanatide comes in tablet form and is taken orally once daily. The recommended dose for CIC is 3 mg per day, while the recommended dose for IBS-C is 1 mg per day.
Plecanatide offers an alternative option for those suffering from CIC and IBS-C. Its targeted approach can lead to effective relief without as many negative side effects commonly associated with traditional treatments.
Plecanatide is an FDA-approved medication used to treat chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C). It works by binding to the guanylate cyclase-C receptor located on the surface of intestinal cells.
When plecanatide binds to this receptor, it stimulates the production of cyclic guanosine monophosphate (cGMP), which promotes fluid secretion into the intestines. This increased fluid helps soften stool, making it easier to pass through the digestive tract.
Furthermore, plecanatide also reduces visceral hypersensitivity in people with IBS-C. Visceral hypersensitivity refers to a heightened sensitivity of internal organs such as the gut, leading to pain and discomfort associated with IBS symptoms like bloating and cramping.
By reducing visceral hypersensitivity, plecanatide can alleviate these uncomfortable symptoms for patients suffering from IBS-C. Plecanatide's mechanism of action provides relief for those who struggle with chronic constipation or IBS-C.
While plecanatide has shown to be effective in treating irritable bowel syndrome, it's important to consider the potential side effects. Like any medication, there can be some negative reactions that patients may experience.
Common side effects of plecanatide include diarrhea, abdominal pain, nausea and vomiting. These symptoms are typically mild to moderate in severity and will often improve over time as the patient continues with treatment.
Plecanatide is a promising treatment option for patients suffering from irritable bowel syndrome with constipation. It works by targeting the guanylate cyclase-C receptor and increasing fluid secretion in the intestines to promote regular bowel movements.
Recent studies have shown that plecanatide is effective in improving symptoms of IBS-C and has a favorable safety profile. However, as with any medication, there are potential side effects that should be carefully monitored.
Medical professionals can confidently consider prescribing plecanatide to their patients with IBS-C who have not responded well to other treatments or who experience bothersome side effects from current therapies.
The availability of plecanatide provides an important new tool for managing this common digestive disorder and improving quality of life for affected individuals.
1.
In Acute Myeloid Leukemia Diagnosed Recently, FLT3 Inhibitor Is Very Effective.
2.
After three years, responses to mounetuzumab in follicular lymphoma are still stable.
3.
Exercise could ease symptoms for people with chronic lymphocytic leukemia, support and guidance are lacking: Study
4.
Biomarker-Selected Treatment Shows Promise for Bladder Preservation in MIBC
5.
Scientists hail the cervical cancer treatment as the most remarkable breakthrough in 20 years.
1.
How EPCORITAMAB is Revolutionizing the Treatment of Cancer
2.
Revolutionizing Cancer Care: The Promise of Early Detection and Biomarkers
3.
Voices That Heal: Redefining Cancer Care Through Patient Insights and Partnership
4.
The Next Generation of Precision: How Multi-Specific Antibodies are Redefining Oncology's Future - A 2025 Review
5.
Can We Repurpose BV-CHP for Better Outcomes in Peripheral T-Cell Lymphoma?
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
From Relapse to Remission: Mapping the Treatment Journey in Adult R/R-Cell ALL - Part 2
2.
An Intro to The Multifaceted Advantages of CDK4/6 Inhibitors in HR+/HER2- Advanced Breast Cancer Clinical Studies.
3.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part IV
4.
The Landscape of First-Line Treatment for Urothelial Carcinoma- The Conclusion
5.
CDK4/6 Inhibitors in Extending Overall Survival in HR+/HER2- aBC Patients in Clinical Trial and Real World
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation